Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a public health burden associated with significant liver-related and unrelated morbidity and mortality [1]. Results of epidemiological studies suggest t...